Glenn Betrus, MD
Urology · Port Huron, MINPI 1376563130
Payments from drug & device makers
Across 204 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$437
- Astellas Pharma US Inc$433
- C. R. Bard, Inc. & Subsidiaries$414
- Merck$398
- Rochester Medical Corporation$353
- Johnson & Johnson$287
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1974%
- Food & beverage$4,07292%
- Education$1483%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 11 | $437 |
| Astellas Pharma US Inc | 26 | $433 |
| C. R. Bard, Inc. & Subsidiaries | 16 | $414 |
| Merck | 11 | $398 |
| Rochester Medical Corporation | 20 | $353 |
| Johnson & Johnson | 16 | $287 |
| Pfizer | 15 | $238 |
| Coloplast | 12 | $203 |
| Sumitomo Pharma America, Inc. | 8 | $154 |
| Myriad Genetic Laboratories, Inc. | 8 | $147 |
| Axonics, Inc. | 7 | $147 |
| Bayer | 3 | $112 |
| Blue Earth Diagnostics | 6 | $109 |
| Endo Pharmaceuticals Inc. | 6 | $103 |
| Janssen Scientific Affairs, LLC | 3 | $101 |
| BD | 4 | $99 |
| AbbVie(2 entities) | 5 | $83 |
| Neotract Inc. | 1 | $75 |
| Amgen | 4 | $69 |
| Tolmar, Inc. | 3 | $60 |
| AstraZeneca | 3 | $49 |
| 180 Medical, Inc. | 2 | $42 |
| Boston Scientific | 1 | $41 |
| Urogen Pharma, Inc. | 1 | $35 |
| Tolmar Pharmaceuticals, Inc. | 2 | $33 |
| Medtronic | 2 | $33 |
| Ambu Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Valencia Technologies Corporation | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $22 |
| Cook Medical LLC | 1 | $21 |
| Urovant Sciences Inc | 1 | $17 |
| Procept Biorobotics Corporation | 1 | $17 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$182
How this compares
$4,417 in reported general payments places this provider in the 60th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 71 | $985,471 |
| MyrbetriqMirabegron | 80 | $74,368 |
| GemtesaVibegron | 50 | $42,600 |
| Potassium Citrate ErPotassium Citrate | 86 | $23,312 |
| Mirabegron ErMirabegron | 15 | $13,597 |
| Trospium Chloride ErTrospium Chloride | 59 | $12,315 |
| Tamsulosin Hcl | 553 | $11,648 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 112 | $10,780 |
| Methenamine Hippurate | 59 | $7,700 |
| Finasteride | 301 | $5,988 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 146 | $3,635 |
| Tolterodine Tartrate ErTolterodine Tartrate | 36 | $3,554 |
| Estradiol | 47 | $2,899 |
| Trospium Chloride | 19 | $874 |
| Solifenacin Succinate | 34 | $863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $433 | $1,059,839151 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $154 | $42,60050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 400 urology providers in Michigan.
Other urology in Port Huron
- Jason HafronWest Bloomfield$9.9M
- Ashok ReddySterling Heights$4.9M
- Kenneth KernenTroy$3.4M
- James PeabodyDetroit$2.1M
- William RobertsAnn Arbor$973K
- Adam GadzinskiRoyal Oak$727K
- William JohnstonLivonia$675K
- Kenneth PetersRoyal Oak$590K
- Khurshid GhaniAnn Arbor$550K
- Richard BennettRoyal Oak$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.